Tempus Reports Third Quarter 2026 Results
Exhibit 99.1 Tempus Reports Third Quarter 2026 Results CHICAGO, November 2, 2026— Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended September 30, 2026.
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky, founder and CEO of Tempus. “These results reinforce the durability of our model as our best-in-class diagnostic platform enhances our data and AI offerings, distinguishes our business from our many competitors, and helps drive our performance quarter after quarter.”
For the three-month period ended September 30, 2026, as compared to the same period in 2025:
• Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and expect full year Adjusted EBITDA of ~$65 million
• Announced multi-year strategic collaboration with Merck and Moderna to support commercialization of their individualized neoantigen therapy (INT) class of drugs
For the three-month period ended September 30, 2026, as compared to the same period in 2025:
• Diagnostics generated $303.5 million of revenue, representing 20% growth, driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of 3%.
• Data and Applications generated $108.1 million of revenue, representing 33% growth, with Insights growing 29%.
• Gross profit increased 27% to $266.7 million, led by growth in Data and Applications.
• Net loss was $(14.9) million, which included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities, compared to a net loss of $(80.0) million in Q3 of 2025.
• Announced a strategic collaboration with BMS in October through which Tempus is directly licensing to BMS oncology data and models for up to $137.5 million over a five-year term. In addition, BMS and Pathos are licensing data for patients with Alzheimer's or dementia for $55 million over a five-year term, extending Tempus’ data and modeling platform beyond oncology.
• Announced a multi-year strategic collaboration with Merck and Moderna to support the potential commercialization of intismeran autogene, a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completed resected stage IIB-IV melanoma and other cancer types. • Cleared regulatory review of pending acquisition of Personalis (Nasdaq: PSNL). Personalis' shareholder meeting to approve the acquisition is planned for November 30, 2026. • Received two 510(k) clearances from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH and ECG-MR, expanding our non-invasive AI cardiology footprint. • Announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical information over the next several years. Third Quarter Financial Results
Financial Outlook and Guidance Tempus is increasing its full year 2026 revenue guidance to $1.60 to $1.605 billion, which represents ~25% annual growth. We continue to expect 2026 Adjusted EBITDA to be ~$65 million. For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com. Webcast and Conference Call Information A conference call and webcast will begin today, November 2, 2026 at 8:45 a.m. Eastern Time. Interested parties may access details at: Conference ID: 579 261 752 United States (Toll-Free): (833) 461-5787 International (Toll): +1 (585) 542-9983 Live webcast can be accessed here The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference call and webcast. About Tempus Tempus is a technology company making precision medicine a reality through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of de-identified multimodal data and an intelligent operating system that makes that data accessible and actionable, Tempus connects AI, diagnostics and clinical workflows to deliver more personalized patient care and accelerate the discovery, development and delivery of better medicines. By continuously transforming data into insights, Tempus is building a learning healthcare ecosystem in which every patient can benefit from the treatment and experiences of those who came before.
For more information, visittempus.comand follow Tempus onLinkedIn,Instagram, andX.
In addition to the financial information presented in this release in accordance with accounting principles generally accepted in the United States of America (GAAP), Tempus also presents adjusted non-GAAP financial measures.
Non-GAAP gross profitis defined as GAAP gross profit, excluding stock-based compensation expense and employer payroll tax related to stock-based compensation (collectively, the “stock-based compensation adjustments”).Non-GAAP gross marginis defined as gross profit, excluding the stock-based compensation adjustments, as a percentage of revenue.Non-GAAP operating expensesare calculated as the sum of technology research and development expense, research and development expense, and selling, general and administrative expense, excluding the stock-based compensation adjustments, acquisition-related expenses, amortization of intangibles due to acquisition, and franchise taxes related to IPO.Non-GAAP income (loss) from operationsis defined as loss from operations, adjusted to exclude (i) the stock-based compensation adjustments, (ii) acquisition-related expenses, (iii) franchise taxes related to IPO, and (iv) amortization of intangibles due to acquisition.Non-GAAP net income (loss)is defined as net loss, adjusted to exclude (i) changes in fair value of our marketable equity securities and indemnity-related holdback liabilities, (ii) the stock-based compensation adjustments, (iii) acquisition-related expenses, (iv) amortization of intangibles due to acquisition, (v) losses (gains) from equity method investments, (vi) provision for (benefit from) income taxes, (vii) franchise taxes related to IPO, (viii) amortization of deferred other income from our IP License Agreement with SB Tempus, and (ix) loss on debt extinguishment.Non-GAAP net income (loss) per shareis defined as non-GAAP net income (loss) divided by weighted average common shares outstanding, basic and diluted.
Adjusted EBITDAis defined as net loss, adjusted to exclude (i) interest income, (ii) interest expense, (iii) depreciation and amortization, (iv) provision for (benefit from) income taxes, (v) losses (gains) from equity method investments, (vi) changes in fair value of our marketable equity securities and indemnity- related holdback liabilities, (vii) the stock-based compensation adjustments, (viii)acquisition-related expenses, (ix) amortization of deferred other income from our IP License Agreement with SB Tempus, (x) franchise taxes related to our IPO, and (xi) loss on debt extinguishment.
Tempus believes these non-GAAP financial measures are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making and they may be used by institutional investors and the analyst community to help them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a key measurement used by Tempus management to make operating decisions, including those related to analyzing operating expenses, evaluating performance, and performing strategic planning and annual budgeting. However, there are a number of limitations related to the use of non-GAAP financial measures, and these non- GAAP measures should be considered in addition to, not as a substitute for or in isolation from, our financial results prepared in accordance with GAAP. Other companies, including companies in our industry, may calculate these non-GAAP financial measures differently or not at all, which reduces their usefulness as comparative measures.
Tempus does not provide guidance for net loss, the most directly comparable GAAP measure to Adjusted EBITDA, and similarly cannot provide a reconciliation between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable effort due to the unavailability of reliable estimates for certain components of net loss and the respective reconciliations. These forecasted items are not within Tempus’ control, may vary greatly between periods, and could significantly impact future financial results.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and its industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, Tempus’ expected financial results for full year 2026; expectations concerning Tempus' collaborations and partnerships; Tempus' competitive position; and the pending acquisition of Personalis. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward- looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may
affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments, including Tempus' ability to consummate the acquisition of Personalis on the contemplated terms or at all and Tempus’ ability to realize the expected benefits of the acquisition of Paige AI, Ambry Genetics, Deep 6 AI, Center Health, and, if consummated, Personalis; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026, as well as in other filings Tempus may make with the SEC from time to time. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Source: Tempus AI, Inc. Tempus AI, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except per share amounts)
(1) Includes related party revenue from Pathos AI, Inc. of $0 and $225 for the three months ended September 30, 2026 and 2025, respectively. Includes related party revenue from Pathos AI, Inc. of $190 and $226 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. (2) Includes related party revenue from Pathos AI, Inc. of $22,061 and $24,907 for the three months ended September 30, 2026 and 2025, respectively. Includes related party revenue from Pathos AI, Inc. of $65,718 and $41,445 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. Also includes related party revenue from SB Tempus Corp. of $0 and $6,253 for the three months ended September 30, 2026 and 2025, respectively. Includes related party revenue from SB Tempus Corp. of $6,241 and $18,743 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture. (3) Includes related party other income from SB Tempus Corp. of $3,989 for each of the three months ended September 30, 2026 and 2025. Includes related party other income from SB Tempus Corp. of $11,966 for each of the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint Venture.
Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except share and per share amounts)
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current Assets Cash and cash equivalents $ 590,479 $ 604,787 Accounts receivable(1), net of allowances of $4,378 and $2,755 at 380,744 311,170 September 30, 2026 and December 31, 2025, respectively Inventory 53,773 51,724 Related party asset 17,500 8,785 Prepaid expenses and other current 47,507 40,498 assets Marketable equity 46,874 150,211 securities Total current assets $ 1,136,877 $ 1,167,175 Property and equipment, net 95,186 89,156 Goodwill 488,142 470,211 Intangible assets, net 293,815 349,202 Capitalized software, net 40,561 6,051 Marketable equity securities, less 212,276 — current portion Investments and other 16,241 21,111 assets Investment in joint venture 77,635 86,557 Investment in related party 17,500 — Related party asset, less current 10,208 16,215 portion Operating lease 58,402 64,496 right-of-use assets Restricted cash 4,755 4,664 Total Assets $ 2,451,598 $ 2,274,838 Liabilities, Convertible redeemable preferred stock, and Stockholders' equity Current Liabilities Accounts payable 70,506 81,994 Related party payable 10,000 — Accrued expenses 232,976 155,370 Deferred revenue(2) 85,931 92,673 Deferred other income(3) 11,966 15,955 Other current liabilities 12,146 8,680 Operating lease liabilities 11,584 13,355 Accrued data licensing fees 1,296 4,361 Total current liabilities $ 436,405 $ 372,388
(1) Includes related party accounts receivable from Pathos AI, Inc. of $12,092 and $6,428 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party accounts receivable from SB Tempus Corp. of $318 and $173 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture. (2) Includes related party deferred revenue from Pathos AI, Inc. of $103 and $3,938 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties. Also includes related party deferred revenue from SB Tempus Corp. of $0 and $6,235 as of September 30, 2026 and December 31, 2025, respectively. Refer to Note 7, Joint Venture. (3) Deferred other income balances solely related to SB Tempus Corp. Refer to Note 7, Joint Venture.
Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except share and per share amounts)
September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Operating lease liabilities, less 69,483 74,272 current portion Convertible 175,967 208,672 promissory note Other long-term 51,449 56,600 liabilities Revolving credit — 100,000 facility Interest payable 22,501 12,393 Long-term debt, net — 202,753 Convertible senior 1,174,877 728,078 notes, net Deferred other income, less current — 7,977 portion(3) Deferred revenue, 20,514 20,379 less current portion Total Liabilities $ 1,951,196 $ 1,783,512 Commitments and contingencies (Note 8) Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at September 30, 2026 $ — $ — and December 31, 2025, respectively, no shares outstanding at September 30, 2026 and December 31, 2025 Stockholders' equity Class A Common Stock, $0.0001 par value, 1,000,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 18 17 177,182,062 and 173,235,428 shares outstanding at September 30, 2026 and December 31, 2025, respectively Class B Common Stock, $0.0001 par value, 5,500,000 shares authorized at September 30, 2026 and December 31, 2025, 1 1 respectively; 5,043,789 outstanding at September 30, 2026 and December 31, 2025, respectively Treasury Stock, 203,431 and 183,229 shares at September (6,642 ) (6,642 ) 30, 2026 and December 31, 2025, respectively, at cost Additional paid-in 3,037,849 2,892,910 capital Accumulated other 166 902 comprehensive income Accumulated deficit (2,530,990 ) (2,395,862 ) Total Stockholders' $ 500,402 $ 491,326 equity Total Liabilities, Convertible redeemable preferred $ 2,451,598 $ 2,274,838 stock, and Stockholders' equity
(3) Deferred other income balances solely related to SB Tempus Corp. Refer to Note 7, Joint Venture.
Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)
Nine Months Ended Operating September 30, activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net loss $ (135,128 ) $ (190,862 ) Adjustments to reconcile net loss to net cash used in operating activities Stock-based 154,901 79,408 compensation Gain on marketable (108,939 ) (4,731 ) equity securities Loss on disposal of property and 375 — equipment Deferred income — (46,216 ) taxes Losses from equity 8,318 2,465 method investments Amortization of original issue 5,008 2,615 discount Amortization of deferred financing 260 398 fees Change in fair value of holdback 1,189 291 liability Loss on debt 11,643 12,034 extinguishment Depreciation and 78,392 75,416 amortization Provision for bad 2,450 767 debt expense Provision for 111 1,135 obsolete inventory Non-cash operating 10,296 7,866 lease costs Minimum accretion 97 109 expense PIK interest added 1,674 8,839 to principal Change in assets and liabilities Accounts (71,839 ) (63,199 ) receivable(1) Inventory (2,160 ) (6,537 ) Prepaid expenses and other current (6,997 ) (3,991 ) assets Investments and 1,883 (16,700 ) other assets Accounts payable (49,250 ) (18,528 ) Related party 7,292 (25,000 ) asset Deferred (24,107 ) 17,398 revenue(2) Deferred other (11,966 ) (11,966 ) income(3) Accrued data (3,180 ) 3,730 licensing fees Accrued expenses & 58,493 (5,179 ) other Interest payable 10,360 10,288 Operating lease (10,762 ) (11,152 ) liabilities Net cash used in operating $ (71,586 ) $ (181,302 ) activities
(1) Includes increase in related party accounts receivable from Pathos AI, Inc. of $5,664 and $2,352 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties. Includes increase in related party accounts receivable from SB Tempus Corp. of $145 and $108 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture. (2) Includes decrease in related party deferred revenue from Pathos AI, Inc. of $3,835 for the nine months ended September 30, 2026. Includes increase in related party deferred revenue from Pathos AI, Inc. of $19,918 for the nine months ended September 30, 2025, respectively. Refer to Note 16, Related Parties. Also includes decrease in related party deferred revenue from SB Tempus Corp. of $6,235 and $18,737 for the nine months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint Venture. (3) Includes decrease in related party deferred other income from SB Tempus Corp. of $11,966 for each of the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint Venture.
Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)
Nine Months Ended Investing September 30, activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Purchases of property and $ (23,665 ) $ (16,294 ) equipment Proceeds from sale of marketable — 8,316 equity securities Business combinations, net (2,763 ) (375,025 ) of cash acquired (Note 4) Capitalized (12,252 ) (4,635 ) software costs Net cash used in investing $ (38,680 ) $ (387,638 ) activities Financing activities Proceeds from convertible senior notes, 443,132 726,497 net of initial purchasers' discount Principal payments (207,717 ) (276,892 ) on long-term debt Principal payments on revolving (100,000 ) — credit facility Prepayment premium (6,433 ) (7,841 ) on long-term debt Payment of deferred offering (264 ) (501 ) costs Purchases of (31,234 ) (41,775 ) capped call Proceeds from revolving credit facility, — 98,000 net of original issue discount Proceeds from long-term debt, net of — 196,000 original issue discount Proceeds from issuance of common stock in connection with — 195,499 at-the-market offering, net of commissions Payment of deferred financing (1,349 ) (1,255 ) fees Net cash provided by financing $ 96,135 $ 887,732 activities Effect of foreign exchange rates on $ (86 ) $ (78 ) cash Net (decrease) increase in Cash, Cash $ (14,217 ) $ 318,714 Equivalents and Restricted Cash Cash, cash equivalents and restricted 609,451 341,835 cash, beginning of period Cash, cash equivalents and restricted $ 595,234 $ 660,549 cash, end of period Cash, Cash Equivalents and Restricted Cash are Comprised of:
Cash and cash $ 590,479 $ 655,918 equivalents Restricted cash and cash 4,755 4,631 equivalents Total cash, cash equivalents and $ 595,234 $ 660,549 restricted cash Supplemental disclosure of cash flow information Cash paid during the year for $ 15,111 $ 37,349 interest Cash paid for $ 246 $ 573 income taxes Preferred stock received on $ 17,500 $ — accounts receivable(4)
(4) Includes related party preferred stock of Pathos AI, Inc. of $17,500 for the nine months ended September 30, 2026.
Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in thousands)
Supplemental disclosure of noncash Nine Months Ended investing and financing September 30, activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Purchases of property and equipment, $ 10,226 $ 3,724 accrued but not paid Redemption of convertible promissory $ 32,705 $ 22,721 note Deferred financing fees, accrued but not $ — $ 489 yet paid Deferred offering costs, accrued but not $ 71 $ 320 yet paid Reclassification of deferred offering costs to additional $ — $ 821 paid-in capital upon at-the-market offering Operating lease liabilities arising from $ 360 $ 22,670 obtaining right-of-use assets Capitalized software costs, accrued but $ 21,536 $ — not yet paid Class A Common Stock issued in $ 13,319 $ 403,154 connection with business combinations Class A Common Stock issued in $ — $ 1,443 connection with license agreement Class A Common Stock issued in $ 6,173 $ — connection with holdback liability Convertible promissory note principal $ — $ 72,488 reset due to amendment
Tempus AI, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (in thousands, except percentages and per share amounts) Diagnostics Gross Profit & Gross Margin
(1) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025. Loss from Operations
(1) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025.
(1) Fair value changes include gains and losses related to quarterly fair value adjustments of our marketable equity securities and indemnity-related holdback liabilities. (2) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025. Adjusted EBITDA
(1) Fair value changes include gains and losses related to quarterly fair value adjustments of our marketable equity securities and indemnity-related holdback liabilities. (2) Acquisition related expenses consist of legal, diligence, accounting, and financing costs incurred for acquisitions during the three and nine months ended September 30, 2026 and 2025.
Full text with the tables
Exhibit 99.1
Tempus Reports Third Quarter 2026 Results
CHICAGO, November 2, 2026— Tempus AI, Inc. (NASDAQ: TEM), a technology company
leading the adoption of AI to advance precision medicine, today reported
financial results for the quarter ended September 30, 2026.
“Q3 was another record quarter, as we delivered $411.5 million of revenue, led
by accelerating unit growth of 32% in our oncology business and increasing
momentum of 33% revenue growth in Data & Applications,” said Eric Lefkofsky,
founder and CEO of Tempus. “These results reinforce the durability of our model
as our best-in-class diagnostic platform enhances our data and AI offerings,
distinguishes our business from our many competitors, and helps drive our
performance quarter after quarter.”
Third Quarter 2026 Highlights
For the three-month period ended September 30, 2026, as compared to the same
period in 2025:
• Total revenue of $411.5 million, an increase of 23%
• Oncology volume growth accelerated to 32%
• Minimal Residual Disease (MRD) volume of ~12,000 tests, up 300%
• Data & Apps revenue increased 33%, with Insights increasing 29%
• Increasing full year 2026 revenue guidance to $1.60 to $1.605 billion and
expect full year Adjusted EBITDA of ~$65 million
• Announced multi-year strategic collaboration with Merck and Moderna to support
commercialization of their individualized neoantigen therapy (INT) class of
drugs
• In October, announced a strategic collaboration with BMS bringing Tempus’
total data licensing bookings to >$550 million year to date
Third Quarter 2026 Summary Results
For the three-month period ended September 30, 2026, as compared to the same
period in 2025:
• Total revenue increased 23% to $411.5 million.
• Diagnostics generated $303.5 million of revenue, representing 20% growth,
driven by Oncology volume growth of 32%, offset by Hereditary revenue growth of
3%.
• Data and Applications generated $108.1 million of revenue, representing 33%
growth, with Insights growing 29%.
• Gross profit increased 27% to $266.7 million, led by growth in Data and
Applications.
• Net loss was $(14.9) million, which included $50.8 million of stock-based
compensation expense and related employer payroll taxes and $42.8 million in
unrealized gains on marketable securities, compared to a net loss of $(80.0)
million in Q3 of 2025.
• Adjusted EBITDA was $25.6 million, compared to $1.5 million in Q3 of 2025.
• Ended the quarter with cash and marketable securities of $854.4 million.
Detailed Operational Highlights
• Announced a strategic collaboration with BMS in October through which Tempus
is directly licensing to BMS oncology data and models for up to $137.5 million
over a five-year term. In addition, BMS and Pathos are licensing data for
patients with Alzheimer's or dementia for $55 million over a five-year term,
extending Tempus’ data and modeling platform beyond oncology.
• Announced a multi-year strategic collaboration with Merck and Moderna to
support the potential commercialization of intismeran autogene, a novel,
potential first-in-class individualized neoantigen therapy (INT) being evaluated
in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in
patients with completed resected stage IIB-IV melanoma and other cancer types.
• Cleared regulatory review of pending acquisition of Personalis (Nasdaq: PSNL).
Personalis' shareholder meeting to approve the acquisition is planned for
November 30, 2026. • Received two 510(k) clearances from the U.S. Food and Drug
Administration (FDA) for Tempus ECG-PH and ECG-MR, expanding our non-invasive AI
cardiology footprint. • Announced an initiative to build a research platform
containing 100,000 whole genomes linked to longitudinal clinical information
over the next several years. Third Quarter Financial Results
Three
Months
Ended
September
30,
2026
(in
thousands,
except
percentag…
and per
share
amounts)
(unaudite… 2025 Change
──────────────────────────────────────────────────────────────────────────────
Revenue $ 411,537 $ 334,206 23 %
Gross $ 266,701 $ 209,942 27 %
profit
Loss from $ (56,864 ) $ (60,996 ) 7 %
operations
Non-GAAP
income
(loss) $ 14,422 $ (8,662 ) 267 %
from
operations
Net loss $ (14,851 ) $ (79,982 ) 81 %
Non-GAAP
net income $ 13,359 $ (19,590 ) 168 %
(loss)
Adjusted $ 25,572 $ 1,476 1,633 %
EBITDA
Net loss
per share, $ (0.08 ) $ (0.46 ) 83 %
basic and
diluted
Non-GAAP
net income
(loss) per $ 0.07 $ (0.11 ) 164 %
share,
basic and
diluted
Financial Outlook and Guidance Tempus is increasing its full year 2026 revenue
guidance to $1.60 to $1.605 billion, which represents ~25% annual growth. We
continue to expect 2026 Adjusted EBITDA to be ~$65 million. For additional
information on the quarter, including a letter from our CEO and CFO, please
visit our investor relations site at investors.tempus.com. Webcast and
Conference Call Information A conference call and webcast will begin today,
November 2, 2026 at 8:45 a.m. Eastern Time. Interested parties may access
details at: Conference ID: 579 261 752 United States (Toll-Free): (833) 461-5787
International (Toll): +1 (585) 542-9983 Live webcast can be accessed here The
webcast may be accessed on the company’s investor relations website at
investors.tempus.com. For those unable to listen to the live webcast, a
recording will be made available on the company’s website after the event and
will be accessible for one year. Visit the investor relations website to find
the company’s latest deck, and commentary on the quarter by Eric Lefkofsky,
Founder and CEO, and Jim Rogers, CFO, which will be discussed on the conference
call and webcast. About Tempus Tempus is a technology company making precision
medicine a reality through the practical application of artificial intelligence
in healthcare. With one of the world’s largest libraries of de-identified
multimodal data and an intelligent operating system that makes that data
accessible and actionable, Tempus connects AI, diagnostics and clinical
workflows to deliver more personalized patient care and accelerate the
discovery, development and delivery of better medicines. By continuously
transforming data into insights, Tempus
is building a learning healthcare ecosystem in which every patient can benefit
from the treatment and experiences of those who came before.
For more information, visittempus.comand follow Tempus onLinkedIn,Instagram,
andX.
Non-GAAP Financial Measures
In addition to the financial information presented in this release in accordance
with accounting principles generally accepted in the United States of America
(GAAP), Tempus also presents adjusted non-GAAP financial measures.
Non-GAAP gross profitis defined as GAAP gross profit, excluding stock-based
compensation expense and employer payroll tax related to stock-based
compensation (collectively, the “stock-based compensation adjustments”).Non-GAAP
gross marginis defined as gross profit, excluding the stock-based compensation
adjustments, as a percentage of revenue.Non-GAAP operating expensesare
calculated as the sum of technology research and development expense, research
and development expense, and selling, general and administrative expense,
excluding the stock-based compensation adjustments, acquisition-related
expenses, amortization of intangibles due to acquisition, and franchise taxes
related to IPO.Non-GAAP income (loss) from operationsis defined as loss from
operations, adjusted to exclude (i) the stock-based compensation adjustments,
(ii) acquisition-related expenses, (iii) franchise taxes related to IPO, and
(iv) amortization of intangibles due to acquisition.Non-GAAP net income (loss)is
defined as net loss, adjusted to exclude (i) changes in fair value of our
marketable equity securities and indemnity-related holdback liabilities, (ii)
the stock-based compensation adjustments, (iii) acquisition-related expenses,
(iv) amortization of intangibles due to acquisition, (v) losses (gains) from
equity method investments, (vi) provision for (benefit from) income taxes, (vii)
franchise taxes related to IPO, (viii) amortization of deferred other income
from our IP License Agreement with SB Tempus, and (ix) loss on debt
extinguishment.Non-GAAP net income (loss) per shareis defined as non-GAAP net
income (loss) divided by weighted average common shares outstanding, basic and
diluted.
Adjusted EBITDAis defined as net loss, adjusted to exclude (i) interest income,
(ii) interest expense, (iii) depreciation and amortization, (iv) provision for
(benefit from) income taxes, (v) losses (gains) from equity method investments,
(vi) changes in fair value of our marketable equity securities and indemnity-
related holdback liabilities, (vii) the stock-based compensation adjustments,
(viii)acquisition-related expenses, (ix) amortization of deferred other income
from our IP License Agreement with SB Tempus, (x) franchise taxes related to our
IPO, and (xi) loss on debt extinguishment.
Tempus believes these non-GAAP financial measures are useful to investors and
others because they allow for additional information with respect to financial
measures used by management in its financial and operational decision-making and
they may be used by institutional investors and the analyst community to help
them analyze the health of Tempus’ business. In particular, Adjusted EBITDA is a
key measurement used by Tempus management to make operating decisions, including
those related to analyzing operating expenses, evaluating performance, and
performing strategic planning and annual budgeting. However, there are a number
of limitations related to the use of non-GAAP financial measures, and these non-
GAAP measures should be considered in addition to, not as a substitute for or in
isolation from, our financial results prepared in accordance with GAAP. Other
companies, including companies in our industry, may calculate these non-GAAP
financial measures differently or not at all, which reduces their usefulness as
comparative measures.
Tempus does not provide guidance for net loss, the most directly comparable GAAP
measure to Adjusted EBITDA, and similarly cannot provide a reconciliation
between Tempus’ forecasted Adjusted EBITDA and net loss without unreasonable
effort due to the unavailability of reliable estimates for certain components of
net loss and the respective reconciliations. These forecasted items are not
within Tempus’ control, may vary greatly between periods, and could
significantly impact future financial results.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and
Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and
its industry that involve substantial risks and uncertainties. All statements
other than statements of historical facts contained in this press release are
forward-looking statements, including, but not limited to, Tempus’ expected
financial results for full year 2026; expectations concerning Tempus'
collaborations and partnerships; Tempus' competitive position; and the pending
acquisition of Personalis. In some cases, you can identify forward-looking
statements because they contain words such as “anticipate,” “believe,”
“contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,”
“may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or the negative of these words or other similar terms or expressions.
Tempus cautions you that the foregoing may not include all of the forward-
looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future
events. Tempus has based the forward-looking statements contained in this press
release primarily on its current expectations and projections about future
events and trends that it believes may
affect Tempus’ business, financial condition, results of operations and
prospects. These forward-looking statements are subject to risks and
uncertainties related to: the intended use of Tempus’ products and services;
Tempus’ financial performance; the ability to attract and retain customers and
partners; managing Tempus’ growth and future expenses; competition and new
market entrants; compliance with new laws, regulations and executive actions,
including any evolving regulations in the artificial intelligence space; the
ability to maintain, protect and enhance Tempus’ intellectual property; the
ability to attract and retain qualified team members and key personnel; the
ability to repay or refinance outstanding debt, or to access additional
financing; future acquisitions, divestitures or investments, including Tempus'
ability to consummate the acquisition of Personalis on the contemplated terms or
at all and Tempus’ ability to realize the expected benefits of the acquisition
of Paige AI, Ambry Genetics, Deep 6 AI, Center Health, and, if consummated,
Personalis; the potential adverse impact of climate change, natural disasters,
health epidemics, macroeconomic conditions, and war or other armed conflict, as
well as risks, uncertainties, and other factors described in the section titled
“Risk Factors” in Tempus’ Form 10-K for the year ended December 31, 2025, filed
with the Securities and Exchange Commission (the "SEC") on February 24, 2026, as
well as in other filings Tempus may make with the SEC from time to time. In
addition, any forward-looking statements contained in this press release are
based on assumptions that Tempus believes to be reasonable as of this date.
Tempus undertakes no obligation to update any forward-looking statements to
reflect events or circumstances after the date of this press release or to
reflect new information or the occurrence of unanticipated events, except as
required by law.
Investors
Kendra Webster
[email protected]
Media
Kelli Manalli
[email protected]
Source: Tempus AI, Inc.
Tempus AI, Inc. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND
COMPREHENSIVE LOSS (Unaudited) (in thousands, except per share amounts)
Three Nine
Mont… Mon…
Ended End…
Sept… Sep…
Net 30, 30,
rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Dia… $ 303,… $ 252,… $ 853,… $ 688…
Data
and 108,… 81,3… 288,… 216…
app…
Tot…
net $ 411,… $ 334,… $ 1,14… $ 904…
rev…
Cost
and
ope…
exp…
Cost
of 114,… 98,6… 323,… 283…
rev…
dia…
Cost
of
rev… 30,7… 25,6… 83,6… 61,…
data
and
app…
Tec…
res… 45,7… 38,0… 135,… 105…
and
dev…
Res…
and 46,0… 44,9… 146,… 122…
dev…
Sel…
gen… 231,… 187,… 670,… 523…
and
adm…
Tot…
cost
and 468,… 395,… 1,35… 1,0…
ope…
exp…
Loss
from $ (56,… ) $ (60,… ) $ (217… ) $ (19… )
ope…
Int… 3,985 4,600 11,7… 7,5…
inc…
Int… (6,7… ) (15,… ) (31,… ) (54… )
exp…
Loss
on — (12,… ) (11,… ) (12… )
debt
ext…
Oth…
inc… 47,1… 2,605 122,… 16,…
net…
Loss
bef…
(pr…
for) $ (12,… ) $ (81,… ) $ (126… ) $ (23… )
ben…
from
inc…
tax…
(Pr…
for)
ben… (35 ) (276 ) (282 ) 45,…
from
inc…
tax…
(Lo…
gai…
from (2,3… ) 1,518 (8,3… ) (2,… )
equ…
met…
inv…
Net $ (14,… ) $ (79,… ) $ (135… ) $ (19… )
loss
Net
loss
per
sha… $ (0.08 ) $ (0.46 ) $ (0.75 ) $ (1.… )
bas…
and
dil…
Wei…
sha…
out…
used
to
com…
net 181,… 174,… 180,… 172…
loss
per
sha…
bas…
and
dil…
Com…
los…
net
of
tax
Net $ (14,… ) $ (79,… ) $ (135… ) $ (19… )
loss
For…
cur… 2,107 (2,9… ) (736 ) 5,4…
tra…
adj…
Com… $ (12,… ) $ (82,… ) $ (135… ) $ (18… )
loss
(1) Includes related party revenue from Pathos AI, Inc. of $0 and $225 for the
three months ended September 30, 2026 and 2025, respectively. Includes related
party revenue from Pathos AI, Inc. of $190 and $226 for the nine months ended
September 30, 2026 and 2025, respectively. Refer to Note 16, Related Parties.
(2) Includes related party revenue from Pathos AI, Inc. of $22,061 and $24,907
for the three months ended September 30, 2026 and 2025, respectively. Includes
related party revenue from Pathos AI, Inc. of $65,718 and $41,445 for the nine
months ended September 30, 2026 and 2025, respectively. Refer to Note 16,
Related Parties. Also includes related party revenue from SB Tempus Corp. of $0
and $6,253 for the three months ended September 30, 2026 and 2025, respectively.
Includes related party revenue from SB Tempus Corp. of $6,241 and $18,743 for
the nine months ended September 30, 2026 and 2025, respectively. Refer to Note
7, Joint Venture. (3) Includes related party other income from SB Tempus Corp.
of $3,989 for each of the three months ended September 30, 2026 and 2025.
Includes related party other income from SB Tempus Corp. of $11,966 for each of
the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint
Venture.
Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands,
except share and per share amounts)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Assets
Current Assets
Cash and cash equivalents $ 590,479 $ 604,787
Accounts receivable(1), net
of
allowances of $4,378 and
$2,755 at 380,744 311,170
September 30, 2026 and
December 31,
2025, respectively
Inventory 53,773 51,724
Related party asset 17,500 8,785
Prepaid expenses and other
current 47,507 40,498
assets
Marketable equity 46,874 150,211
securities
Total current assets $ 1,136,877 $ 1,167,175
Property and equipment, net 95,186 89,156
Goodwill 488,142 470,211
Intangible assets, net 293,815 349,202
Capitalized software, net 40,561 6,051
Marketable equity
securities, less 212,276 —
current portion
Investments and other 16,241 21,111
assets
Investment in joint venture 77,635 86,557
Investment in related party 17,500 —
Related party asset, less
current 10,208 16,215
portion
Operating lease 58,402 64,496
right-of-use assets
Restricted cash 4,755 4,664
Total Assets $ 2,451,598 $ 2,274,838
Liabilities, Convertible
redeemable
preferred stock, and
Stockholders'
equity
Current Liabilities
Accounts payable 70,506 81,994
Related party payable 10,000 —
Accrued expenses 232,976 155,370
Deferred revenue(2) 85,931 92,673
Deferred other income(3) 11,966 15,955
Other current liabilities 12,146 8,680
Operating lease liabilities 11,584 13,355
Accrued data licensing fees 1,296 4,361
Total current liabilities $ 436,405 $ 372,388
(1) Includes related party accounts receivable from Pathos AI, Inc. of $12,092
and $6,428 as of September 30, 2026 and December 31, 2025, respectively. Refer
to Note 16, Related Parties. Also includes related party accounts receivable
from SB Tempus Corp. of $318 and $173 as of September 30, 2026 and December 31,
2025, respectively. Refer to Note 7, Joint Venture. (2) Includes related party
deferred revenue from Pathos AI, Inc. of $103 and $3,938 as of September 30,
2026 and December 31, 2025, respectively. Refer to Note 16, Related Parties.
Also includes related party deferred revenue from SB Tempus Corp. of $0 and
$6,235 as of September 30, 2026 and December 31, 2025, respectively. Refer to
Note 7, Joint Venture. (3) Deferred other income balances solely related to SB
Tempus Corp. Refer to Note 7, Joint Venture.
Tempus AI, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands,
except share and per share amounts)
September 30, 2026 December 31, 2025
──────────────────────────────────────────────────────────────────────────────
Operating lease
liabilities, less 69,483 74,272
current portion
Convertible 175,967 208,672
promissory note
Other long-term 51,449 56,600
liabilities
Revolving credit — 100,000
facility
Interest payable 22,501 12,393
Long-term debt, net — 202,753
Convertible senior 1,174,877 728,078
notes, net
Deferred other
income, less current — 7,977
portion(3)
Deferred revenue, 20,514 20,379
less current portion
Total Liabilities $ 1,951,196 $ 1,783,512
Commitments and
contingencies (Note
8)
Convertible
redeemable preferred
stock,
$0.0001 par value,
20,000,000 shares
authorized at
September 30, 2026 $ — $ —
and
December 31, 2025,
respectively, no
shares outstanding at
September 30, 2026
and December 31, 2025
Stockholders' equity
Class A Common Stock,
$0.0001 par value,
1,000,000,000 shares
authorized at
September 30, 2026
and December 31,
2025, respectively; 18 17
177,182,062 and
173,235,428 shares
outstanding at
September 30, 2026
and December 31,
2025, respectively
Class B Common Stock,
$0.0001 par value,
5,500,000 shares
authorized at
September
30, 2026 and December
31, 2025, 1 1
respectively;
5,043,789 outstanding
at
September 30, 2026
and December 31,
2025, respectively
Treasury Stock,
203,431 and 183,229
shares at September (6,642 ) (6,642 )
30, 2026 and
December 31, 2025,
respectively, at cost
Additional paid-in 3,037,849 2,892,910
capital
Accumulated other 166 902
comprehensive income
Accumulated deficit (2,530,990 ) (2,395,862 )
Total Stockholders' $ 500,402 $ 491,326
equity
Total Liabilities,
Convertible
redeemable preferred $ 2,451,598 $ 2,274,838
stock, and
Stockholders' equity
(3) Deferred other income balances solely related to SB Tempus Corp. Refer to
Note 7, Joint Venture.
Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in
thousands)
Nine Months Ended
Operating September 30,
activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net loss $ (135,128 ) $ (190,862 )
Adjustments to
reconcile net loss
to net
cash used in
operating
activities
Stock-based 154,901 79,408
compensation
Gain on marketable (108,939 ) (4,731 )
equity securities
Loss on disposal
of property and 375 —
equipment
Deferred income — (46,216 )
taxes
Losses from equity 8,318 2,465
method investments
Amortization of
original issue 5,008 2,615
discount
Amortization of
deferred financing 260 398
fees
Change in fair
value of holdback 1,189 291
liability
Loss on debt 11,643 12,034
extinguishment
Depreciation and 78,392 75,416
amortization
Provision for bad 2,450 767
debt expense
Provision for 111 1,135
obsolete inventory
Non-cash operating 10,296 7,866
lease costs
Minimum accretion 97 109
expense
PIK interest added 1,674 8,839
to principal
Change in assets
and liabilities
Accounts (71,839 ) (63,199 )
receivable(1)
Inventory (2,160 ) (6,537 )
Prepaid expenses
and other current (6,997 ) (3,991 )
assets
Investments and 1,883 (16,700 )
other assets
Accounts payable (49,250 ) (18,528 )
Related party 7,292 (25,000 )
asset
Deferred (24,107 ) 17,398
revenue(2)
Deferred other (11,966 ) (11,966 )
income(3)
Accrued data (3,180 ) 3,730
licensing fees
Accrued expenses & 58,493 (5,179 )
other
Interest payable 10,360 10,288
Operating lease (10,762 ) (11,152 )
liabilities
Net cash used in
operating $ (71,586 ) $ (181,302 )
activities
(1) Includes increase in related party accounts receivable from Pathos AI, Inc.
of $5,664 and $2,352 for the nine months ended September 30, 2026 and 2025,
respectively. Refer to Note 16, Related Parties. Includes increase in related
party accounts receivable from SB Tempus Corp. of $145 and $108 for the nine
months ended September 30, 2026 and 2025, respectively. Refer to Note 7, Joint
Venture. (2) Includes decrease in related party deferred revenue from Pathos AI,
Inc. of $3,835 for the nine months ended September 30, 2026. Includes increase
in related party deferred revenue from Pathos AI, Inc. of $19,918 for the nine
months ended September 30, 2025, respectively. Refer to Note 16, Related
Parties. Also includes decrease in related party deferred revenue from SB Tempus
Corp. of $6,235 and $18,737 for the nine months ended September 30, 2026 and
2025, respectively. Refer to Note 7, Joint Venture. (3) Includes decrease in
related party deferred other income from SB Tempus Corp. of $11,966 for each of
the nine months ended September 30, 2026 and 2025. Refer to Note 7, Joint
Venture.
Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in
thousands)
Nine Months Ended
Investing September 30,
activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Purchases of
property and $ (23,665 ) $ (16,294 )
equipment
Proceeds from sale
of marketable — 8,316
equity
securities
Business
combinations, net (2,763 ) (375,025 )
of cash
acquired (Note 4)
Capitalized (12,252 ) (4,635 )
software costs
Net cash used in
investing $ (38,680 ) $ (387,638 )
activities
Financing
activities
Proceeds from
convertible senior
notes, 443,132 726,497
net of initial
purchasers'
discount
Principal payments (207,717 ) (276,892 )
on long-term debt
Principal payments
on revolving (100,000 ) —
credit
facility
Prepayment premium (6,433 ) (7,841 )
on long-term debt
Payment of
deferred offering (264 ) (501 )
costs
Purchases of (31,234 ) (41,775 )
capped call
Proceeds from
revolving credit
facility, — 98,000
net of original
issue discount
Proceeds from
long-term debt,
net of — 196,000
original issue
discount
Proceeds from
issuance of common
stock
in connection with — 195,499
at-the-market
offering, net of
commissions
Payment of
deferred financing (1,349 ) (1,255 )
fees
Net cash provided
by financing $ 96,135 $ 887,732
activities
Effect of foreign
exchange rates on $ (86 ) $ (78 )
cash
Net (decrease)
increase in Cash,
Cash $ (14,217 ) $ 318,714
Equivalents and
Restricted Cash
Cash, cash
equivalents and
restricted 609,451 341,835
cash, beginning of
period
Cash, cash
equivalents and
restricted $ 595,234 $ 660,549
cash, end of
period
Cash, Cash
Equivalents and
Restricted
Cash are Comprised
of:
Cash and cash $ 590,479 $ 655,918
equivalents
Restricted cash
and cash 4,755 4,631
equivalents
Total cash, cash
equivalents and $ 595,234 $ 660,549
restricted cash
Supplemental
disclosure of cash
flow
information
Cash paid during
the year for $ 15,111 $ 37,349
interest
Cash paid for $ 246 $ 573
income taxes
Preferred stock
received on $ 17,500 $ —
accounts
receivable(4)
(4) Includes related party preferred stock of Pathos AI, Inc. of $17,500 for the
nine months ended September 30, 2026.
Tempus AI, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (in
thousands)
Supplemental disclosure
of noncash Nine Months Ended
investing and financing September 30,
activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Purchases of property
and equipment, $ 10,226 $ 3,724
accrued but not paid
Redemption of
convertible promissory $ 32,705 $ 22,721
note
Deferred financing
fees, accrued but not $ — $ 489
yet paid
Deferred offering
costs, accrued but not $ 71 $ 320
yet paid
Reclassification of
deferred offering
costs to additional $ — $ 821
paid-in capital upon
at-the-market offering
Operating lease
liabilities arising
from $ 360 $ 22,670
obtaining right-of-use
assets
Capitalized software
costs, accrued but $ 21,536 $ —
not yet paid
Class A Common Stock
issued in $ 13,319 $ 403,154
connection with
business combinations
Class A Common Stock
issued in $ — $ 1,443
connection with license
agreement
Class A Common Stock
issued in $ 6,173 $ —
connection with
holdback liability
Convertible promissory
note principal $ — $ 72,488
reset due to amendment
Tempus AI, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures
(Unaudited) (in thousands, except percentages and per share amounts) Diagnostics
Gross Profit & Gross Margin
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Dia… $ 303,… $ 252,… $ 853,… $ 688,…
rev…
Cost
of 114,… 98,6… 323,… 283,…
rev…
dia…
Gro…
pro… $ 189,… $ 154,… $ 530,… $ 405,…
dia…
Sto…
com… 3,037 1,631 8,795 4,086
exp…
Emp…
pay…
tax
rel… 150 36 608 338
to
sto…
com…
Non…
gro… $ 192,… $ 155,… $ 540,… $ 409,…
pro…
dia…
Dia…
gro… 62.4 % 61.0 % 62.1 % 58.9 %
mar…
Sto…
com… 1.0 % 0.6 % 1.0 % 0.6 %
exp…
Emp…
pay…
tax
rel… 0.0 % 0.0 % 0.1 % 0.0 %
to
sto…
com…
Non…
gro… 63.5 % 61.7 % 63.2 % 59.5 %
mar…
dia…
Data and applications Gross Profit & Gross Margin
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Data
and $ 108,… $ 81,3… $ 288,… $ 216,…
app…
rev…
Cost
of
rev… 30,7… 25,6… 83,6… 61,2…
data
and
app…
Gro…
pro…
data $ 77,2… $ 55,7… $ 204,… $ 154,…
and
app…
Sto…
com… 1,214 894 3,735 2,198
exp…
Emp…
pay…
tax
rel… 94 62 331 220
to
sto…
com…
Non…
gro…
pro… $ 78,5… $ 56,6… $ 208,… $ 157,…
data
and
app…
Gro…
mar…
data 71.5 % 68.5 % 71.0 % 71.7 %
and
app…
Sto…
com… 1.1 % 1.1 % 1.3 % 1.0 %
exp…
Emp…
pay…
tax
rel… 0.1 % 0.1 % 0.1 % 0.1 %
to
sto…
com…
Non…
gro…
mar… 72.7 % 69.7 % 72.4 % 72.8 %
data
and
app…
Total Gross Profit & Gross Margin
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 411,… $ 334,… $ 1,14… $ 904,…
rev…
Cost
of 144,… 124,… 406,… 344,…
rev…
Gro… $ 266,… $ 209,… $ 735,… $ 560,…
pro…
Sto…
com… 4,251 2,525 12,5… 6,284
exp…
Emp…
pay…
tax
rel… 245 98 940 558
to
sto…
com…
Non…
gro… $ 271,… $ 212,… $ 748,… $ 567,…
pro…
Gro… 64.8 % 62.8 % 64.4 % 61.9 %
mar…
Sto…
com… 1.0 % 0.8 % 1.1 % 0.7 %
exp…
Emp…
pay…
tax
rel… 0.1 % 0.0 % 0.1 % 0.1 %
to
sto…
com…
Non…
gro… 65.9 % 63.6 % 65.6 % 62.7 %
mar…
Operating Expenses
Three Nine
Months Months
Ended Ended
Septem… Septemb…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Techno…
resear… $ 45,708 $ 38,087 $ 135,558 $ 105,960
and
develo…
Stock-…
compen… 7,954 5,463 26,101 12,067
expense
Employ…
payroll
tax
related 615 278 1,785 1,034
to
stock-…
compen…
Non-GA…
techno…
resear… $ 37,139 $ 32,346 $ 107,672 $ 92,859
and
develo…
Resear…
and $ 46,000 $ 44,960 $ 146,874 $ 122,453
develo…
Stock-…
compen… 5,432 3,301 15,284 7,618
expense
Employ…
payroll
tax
related 274 122 1,005 533
to
stock-…
compen…
Non-GA…
resear… $ 40,294 $ 41,537 $ 130,585 $ 114,302
and
develo…
Sellin…
general $ 231,857 $ 187,891 $ 670,296 $ 523,230
and
admini…
Stock-…
compen… 30,437 22,690 100,986 53,439
expense
Employ…
payroll
tax
related 1,615 541 4,071 6,040
to
stock-…
compen…
Acquis…
related 3,728 552 4,714 6,073
expens…
Amorti…
of
intang… 16,735 16,764 50,207 44,691
due to
acquis…
Franch…
taxes — — — 1,647
related
to IPO
Non-GA…
sellin…
general $ 179,342 $ 147,344 $ 510,318 $ 411,340
and
admini…
Operat… $ 323,565 $ 270,938 $ 952,728 $ 751,643
expens…
Stock-…
compen… 43,823 31,454 142,371 73,124
expense
Employ…
payroll
tax
related 2,503 941 6,860 7,607
to
stock-…
compen…
Acquis…
related 3,728 552 4,714 6,073
expens…
Amorti…
of
intang… 16,735 16,764 50,207 44,691
due to
acquis…
Franch…
taxes — — — 1,647
related
to IPO
Non-GA…
operat… $ 256,776 $ 221,227 $ 748,576 $ 618,501
expens…
(1) Acquisition related expenses consist of legal, diligence, accounting, and
financing costs incurred for acquisitions during the three and nine months ended
September 30, 2026 and 2025. Loss from Operations
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Loss
from $ (56,… ) $ (60,… ) $ (217… ) $ (191… )
ope…
Sto…
com… 48,0… 33,9… 154,… 79,4…
exp…
Emp…
pay…
tax
rel… 2,749 1,039 7,800 8,165
to
sto…
com…
Acq…
rel… 3,728 552 4,714 6,073
exp…
Fra…
tax…
rel… — — — 1,647
to
IPO
Amo…
of
int… 16,7… 16,7… 50,2… 44,6…
due
to
acq…
Non…
inc…
(lo… $ 14,4… $ (8,6… ) $ 134 $ (51,… )
from
ope…
(1) Acquisition related expenses consist of legal, diligence, accounting, and
financing costs incurred for acquisitions during the three and nine months ended
September 30, 2026 and 2025.
Earnings per Share
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ (14,… ) $ (79,… ) $ (135… ) $ (190… )
loss
Fair
val… (41,… ) 1,255 (107… ) (4,4… )
cha…
Sto…
com… 48,0… 33,9… 154,… 79,4…
exp…
Emp…
pay…
tax
rel… 2,749 1,039 7,800 8,165
to
sto…
com…
Acq…
rel… 3,728 552 4,714 6,073
exp…
Amo…
of
int… 16,7… 16,7… 50,2… 44,6…
due
to
acq…
Los…
(ga…
from 2,368 (1,5… ) 8,318 2,465
equ…
met…
inv…
Pro…
for
(be… 35 276 282 (45,… )
fro…
inc…
tax…
Fra…
tax…
rel… — — — 1,647
to
IPO
Amo…
of (3,9… ) (3,9… ) (11,… ) (11,… )
tec…
lic…
Loss
on — 12,0… 11,6… 12,0…
debt
ext…
Non…
net $ 13,3… $ (19,… ) $ (16,… ) $ (98,… )
inc…
(lo…
Non…
net
inc…
(lo…
per $ 0.07 $ (0.11 ) $ (0.09 ) $ (0.57 )
sha…
bas…
and
dil…
Wei…
ave…
com…
sha… 181,… 174,… 180,… 172,…
out…
bas…
and
dil…
(1) Fair value changes include gains and losses related to quarterly fair value
adjustments of our marketable equity securities and indemnity-related holdback
liabilities. (2) Acquisition related expenses consist of legal, diligence,
accounting, and financing costs incurred for acquisitions during the three and
nine months ended September 30, 2026 and 2025. Adjusted EBITDA
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net $ (14,… ) $ (79,… ) $ (135… ) $ (190… )
loss
Int… (3,9… ) (4,6… ) (11,… ) (7,5… )
inc…
Int… 6,701 15,3… 31,3… 54,9…
exp…
Dep… 7,338 8,120 21,8… 24,3…
Amo… 18,8… 18,9… 56,5… 51,0…
Pro…
for
(be… 35 276 282 (45,… )
fro…
inc…
tax…
EBI… $ 14,1… $ (41,… ) $ (36,… ) $ (113… )
Los…
(ga…
from 2,368 (1,5… ) 8,318 2,465
equ…
met…
inv…
Fair
val… (41,… ) 1,255 (107… ) (4,4… )
cha…
Sto…
com… 48,0… 33,9… 154,… 79,4…
exp…
Emp…
pay…
tax
rel… 2,749 1,039 7,800 8,165
to
sto…
com…
Acq…
rel… 3,728 552 4,714 6,073
exp…
Amo…
of (3,9… ) (3,9… ) (11,… ) (11,… )
tec…
lic…
Fra…
tax…
rel… — — — 1,647
to
IPO
Loss
on — 12,0… 11,6… 12,0…
debt
ext…
Adj… $ 25,5… $ 1,476 $ 30,7… $ (20,… )
EBI…
(1) Fair value changes include gains and losses related to quarterly fair value
adjustments of our marketable equity securities and indemnity-related holdback
liabilities. (2) Acquisition related expenses consist of legal, diligence,
accounting, and financing costs incurred for acquisitions during the three and
nine months ended September 30, 2026 and 2025.